Terms: = Kidney tumors AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin AND Treatment
172 results:
1. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract] [Full Text] [Related]
2. Patients' and physicians' awareness of clinical symptoms and disease severity in tuberous sclerosis complex.
Sauter M; Weber L; Jung D; Weremko M; Bachmann D; Fischereder M; Bachmann HS
Orphanet J Rare Dis; 2024 Mar; 19(1):106. PubMed ID: 38459571
[TBL] [Abstract] [Full Text] [Related]
3. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
[TBL] [Abstract] [Full Text] [Related]
4. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract] [Full Text] [Related]
5. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
[TBL] [Abstract] [Full Text] [Related]
6. Identification of a Novel tsc2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
7. [Expert consensus on the diagnosis and management of Birt-Hogg-Dubé syndrome].
; ; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Sep; 46(9):897-908. PubMed ID: 37670643
[TBL] [Abstract] [Full Text] [Related]
8. Microscopic kidney Disease in Tuberous Sclerosis Complex and treatment With mTOR Inhibition.
Kronick J; Gabril MY; House AA
Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
[TBL] [Abstract] [Full Text] [Related]
9. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Kademane K; Chai Soon Hou S; Jocelyn TXY; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011272. PubMed ID: 37432030
[TBL] [Abstract] [Full Text] [Related]
10. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Navale P; Chatterjee D; Itani M; Trikalinos NA
Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
[TBL] [Abstract] [Full Text] [Related]
11. Potent saccharinate-containing palladium(II) complexes for sensitization to cancer therapy.
Ouyang R; Wang S; Feng K; Liu C; Silva DZ; Chen Y; Zhao Y; Liu B; Miao Y; Zhou S
J Inorg Biochem; 2023 Jul; 244():112205. PubMed ID: 37028114
[TBL] [Abstract] [Full Text] [Related]
12.
Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
[TBL] [Abstract] [Full Text] [Related]
13. treatment Strategies for Hereditary kidney Cancer: Current Recommendations and Updates.
Singh S; Chaurasia A; Gopal N; Malayeri A; Ball MW
Discov Med; 2022; 34(173):205-220. PubMed ID: 36602871
[TBL] [Abstract] [Full Text] [Related]
14. Clinical features and outcomes of male patients with lymphangioleiomyomatosis: A review.
Zhang H; Hu Z; Wang S; Wu K; Yang Q; Song X
Medicine (Baltimore); 2022 Dec; 101(52):e32492. PubMed ID: 36596036
[TBL] [Abstract] [Full Text] [Related]
15. Tuberous Sclerosis Complex: Genetic counselling and perinatal follow-up.
Touraine R; Hauet Q; Harzallah I; Baruteau AE
Arch Pediatr; 2022 Dec; 29(5S):5S3-5S7. PubMed ID: 36585068
[TBL] [Abstract] [Full Text] [Related]
16. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract] [Full Text] [Related]
17. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Wang Z; Zhang W; Fan Y; Zhang X
Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
[TBL] [Abstract] [Full Text] [Related]
18. Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions.
Gallo-Bernal S; Kilcoyne A; Gee MS; Paul E
Pediatr Nephrol; 2023 Oct; 38(10):3253-3264. PubMed ID: 36445479
[TBL] [Abstract] [Full Text] [Related]
19. Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus: A case report.
Koh JS; Oh S; Chung C
Medicine (Baltimore); 2022 Sep; 101(38):e30554. PubMed ID: 36197220
[TBL] [Abstract] [Full Text] [Related]
20. Construction of tsc2 knockout cell line using CRISPR/Cas9 system and demonstration of its effects on NIH-3T3 cells.
Wang X; Zhao Y; Wang Z; Liao Z; Zhang Y
Cell Biochem Biophys; 2022 Dec; 80(4):681-687. PubMed ID: 36181622
[TBL] [Abstract] [Full Text] [Related]
[Next]
